RTW startup signs autoimmune antibody deal Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M Tue W Th F 16 December, 2025

Biopharma’s year doesn’t start on January 1. It starts in San Francisco. Join Endpoints for bold conversations with the leaders shaping what's next. Plus, get access to the Endpoints Hub — our premium coworking and meeting space just steps from the action. Reserve your spot now.

presented by Strength in rar­i­ty: Why biotech spon­sors are dou­bling down on rare on­col­o­gy con­sor­tia

SPOTLIGHT In Focus China has a cheap, quick and quiet way to test novel therapies. Western genetic medicine makers want in

news Sanofi licenses Korean biotech’s tau-targeting Alzheimer’s drug for $80M upfront FDA extends decision on Aldeyra's dry eye disease drug RTW startup signs autoimmune antibody pact with China’s GenSci

Client Engagement Mgr - Life Sciences Strategy & Intelligence Sedulo Group Remote Analyst – Life Sciences Strategy & Intelligence Sedulo Group Remote Recruit talent with Endpoints Careers Contact Meg Estacio: mestacio@endpointsnews.com

Jan 22 12:00pm ET Scaling for a New Era: The Rise of Radiopharma sponsored by PharmaLogic Dec 16 11:30am ET Ensure EU GMP Annex I compliance while maintaining sterile injectable manufacturing excellence & agility sponsored by Grand River Dec 17 12:00pm ET Genetic cohorting and therapeutic response in CKD: Real-world insights from RenasightIQ™ sponsored by Natera

ENDPOINTS PHARMA Gilead posts second Phase 3 win for new HIV-fighting drug regimen Lenz discloses case of retinal tear in presbyopia eye drop patient FDA wants to use more real-world data and calls again for early-phase trials reform FDA fast tracks J&J's multiple myeloma treatment shortly after Phase 3 data release Enhertu combo wins FDA approval for first-line use in HER2+ metastatic breast cancer With GLP-1 microdoses, Noom targets lower-BMI group outside FDA obesity drug labels Milestone finally wins FDA approval for arrythmia nasal spray

in case you missed it 1. Areteia Therapeutics, a $425M bet on asthma disorder, to wind down after terminating Phase 3 studies 2. Sanofi returns to Dren Bio for another B cell depletion therapy at $100M upfront •